Homocysteine thiolactone, an active metabolite of Hcy, has been demonstrated to disrupt tyrosine phosphorylation in the insulin receptor β-subunit and related substrates, hindering phosphatidylinositol 3-kinase activity and subsequently reducing insulin-mediated glycogen synthesis, a key factor in the development of insulin resistance (46). This evidence concerns the gene INS and Insulin resistance.